arrow
A

Ana Vivancos

Vall d'Hebron Barcelona Hospital Campus
H指数:49
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial

Talazoparib联合恩扎卢胺治疗高负荷转移性激素未治前列腺癌:一项随机Ⅱ期试验

2026-10-140
OAAI
Fibroblastic aspartoacylase suppresses TGFβ-mediated responses and cancer progression

成纤维细胞样天冬氨酸酰酶抑制TGFβ介导的反应和癌症进展

2026-06-160
OAAI
Evolving landscape of targeted therapies in early phase clinical trials

靶向疗法在早期临床试验中的演变格局

2026-04-120
PRE
Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors

基因组可操作性及匹配的靶向疗法在为期十年的机构实体瘤精准医学项目中的应用

2025-11-060
OAAI
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy

HER2DX在HER2阳性早期乳腺癌老年患者中的应用:来自RESPECT试验中曲妥珠单抗±化疗的扩展随访研究

2025-11-040
OAAI
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial

PD1疗法在PD1高表达mRNA肿瘤中的疗效:SOLTI-1904 ACROPOLI II期试验中队列1和队列2的结果

2025-09-300
OAAI
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis

HER2DX和早期HER2阳性乳腺癌的生存结局:一项基于个体患者水平的荟萃分析

2025-07-140
PRE
Identifying germline pathogenic variants in breast cancer using tumor sequencing

通过肿瘤测序鉴定乳腺癌中的生殖系致病性变异

BREAST
IF7.9
2025-06-010
OAAI
Correlation of the HER2DX Genomic Test withPathologic Features in Early-Stage HER2+BreastCancer
2025-03-010
PRE
Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression
2025-01-050
OAAI
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer
2025-01-010
OAAI
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer

III期结肠癌患者随访中发现与疾病进展和化疗无关的术后后遗症

2024-10-010
OAAI
Five latent factors underlie response to immunotherapy

免疫疗法反应的五个潜在因素

2024-09-120
OAAI
Pan-cancer homologous recombination deficiency (HRD) evaluation in patients enrolled in a routine molecular screening program

泛癌种同源重组缺陷(HRD)在参与常规分子筛查项目的患者中的评估

2024-09-010
PRE
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer
2024-09-012
PRE
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response
2024-07-111
OAAI